

# Efficient Detection of Highly Mutated Regions with Mutations Overburdening Annotations Tool (MOAT)

Lucas Lochovsky<sup>1,2</sup>, Jing Zhang<sup>1,2</sup> and Mark Gerstein<sup>1,2,3\*</sup>

<sup>1</sup>Program in Computational Biology and Bioinformatics, Yale University, New Haven, Connecticut 06520, USA

<sup>2</sup>Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut 06520, USA

<sup>3</sup>Department of Computer Science, Yale University, New Haven, Connecticut 06520, USA

Received on XXXXX; revised on XXXXX; accepted on XXXXX

Associate Editor: XXXXXXX

## ABSTRACT

High throughput sequencing of [genomes for patients with genetic diseases](#) has opened up the possibility of finding the precise causes of these diseases, paving the way for more effective drug development for these illnesses in the future. However, the analysis of this data has not kept pace with the data's production rate. Fast, [and efficient analysis](#) is necessary to meaningfully interpret this data and derive actionable results. Here, we introduce the Mutations Overburdening Annotations Tool (MOAT), a new computational tool designed to identify functional annotations with a high mutation burden relative to the surrounding genome. Such annotations may be potential driver elements in genetic disease. We release an implementation that offers users two forms of [mutation burden analysis through empirical permutations](#), as well as serial and parallel versions of each form. We also demonstrate MOAT's capability for finding known noncoding drivers in cancer variant data.

**Availability:** MOAT is available at [moat.gersteinlab.org](#)

## 2 INTRODUCTION

High throughput sequencing of genetic disease cohorts has enabled the identification of the molecular causes of these illnesses. This data can be utilized to find the somatic single nucleotide variants (SNVs) in each patient. However, due to the relatively high number of neutral variants in such patients' genomes, it is not immediately apparent which variants are directly connected to the disease phenotype. A common strategy for addressing this issue is to look for genomic elements with a high accumulation of variants. By modeling the factors that influence the stochastic mutation rate, the elements that are more mutated than expected under the background model can be determined.

One means of detecting deviation from the expected background mutation rate is to look for elements that have a high variant density compared to the immediately surrounding genome. [It is well known that](#) the background mutation rate [is highly heterogeneous across the whole genome due to the confounding effect from numerous genomic features](#). Our Mutations Overburdening Annotations Tool (MOAT) is designed to automatically [overcome such](#)

[confounding effect in a non-parametric way](#) and compute the significance of the mutation burden of any element.

MOAT offers users two types of permutation algorithm to empirically assess the background mutation rate, [MOAT-a \(annotation centric\)](#) and [MOAT-v \(variant-centric\)](#). In the following sections, we will describe the implementation of MOAT for parallel computer systems, which enables highly efficient data size scalability. This scalability is important for guaranteeing a reasonable running time given the high computational intensity of the permutation step.

## 3 METHODS

MOAT takes two input files: the annotation file (*afile*) and the variant file (*vfile*).

### 3.1 MOAT-a: Annotation-centric Permutation

The parallel version of MOAT's annotation-centric permutation algorithm, MOAT-a, is a C++ program that uses NVIDIA's CUDA language ([Nickolls, et al., 2008](#)) to instantiate parallel [graphics processing unit \(GPU\)](#) threads, and divides the computational workload across these threads. MOAT-a's steps are illustrated in Fig. 1. [MOAT-a](#) iterates through the annotations, computing the intersecting variant count per annotation. [It then defined an extended region with](#) a user-defined distance [centered at](#) the current input annotation, and randomly [moves the annotation within this extended region](#). MOAT-a will find the [variant counts](#) from the *vfile* that intersect each of the random bins, [which](#) are compared to the input annotation's variant count. The input annotation's *p*-value is defined as the [fraction](#) of bins with a variant count equal to or greater than the input annotation's variant count.

MOAT-a's operations are well suited for massively parallel computing. Therefore, we adapted MOAT-a into a CUDA program, which enables the [parallelization of the computational workload](#) on [graphics processing units \(GPUs\)](#). GPUs are [optimal for programs with high computational intensity and low memory requirements](#). For our purposes, the variant and annotation data are [copied to the GPU's memory](#), and [the stream processors are employed to perform](#) thousands of [permutation calculations](#) in parallel.

\*To whom correspondence should be addressed.

New version 3/11/2016 8:31 PM

Deleted: <#>-CATEGORY .

New version 3/11/2016 8:31 PM

Deleted: Annotations

New version 3/11/2016 8:31 PM

Formatted ... [1]

New version 3/11/2016 8:31 PM

Deleted: \*, ...<sup>2</sup>, Jing Zhang<sup>2</sup>...hang<sup>1</sup>... [2]

New version 3/11/2016 8:31 PM

Deleted: <sup>1</sup>Department of XXXXXXX, Address XXXX etc. .

New version 3/11/2016 8:31 PM

Deleted: XXXXXXX, Address XXXX etc.

New version 3/11/2016 8:31 PM

Deleted: disease patient genomes. ... [3]

New version 3/11/2016 8:31 PM

Deleted: MOAT simulates the background distribution of somatic mutations in the human genome by creating permutations of the input variant set. In other words, given the number of samples and variants in the input file, how would those variants be distributed under the assumption that they arose solely due to background mutation processes? To answer this question, MOAT calculates new positions for each variant in the input set, accounting for mutability factors in the local genome c... [6]

New version 3/11/2016 8:31 PM

Moved down [1]: (Gabriel, et al., 2004).

New version 3/11/2016 8:31 PM

Deleted: Additionally, we evaluate M... [8]

New version 3/11/2016 8:31 PM

Formatted ... [7]

New version 3/11/2016 8:31 PM

Deleted: based

Lucas Lochovsky 1/23/2016 4:16 PM

Comment [1]: Need to add this

New version 3/11/2016 8:31 PM

Deleted: [...]

New version 3/11/2016 8:31 PM

Formatted: ParaNoInd

New version 3/11/2016 8:31 PM

Deleted: based...entric permutation a... [9]

New version 3/11/2016 8:31 PM

Deleted: background

New version 3/11/2016 8:31 PM

Deleted: acceleration...arallelization ... [10]

New version 3/11/2016 8:31 PM

Deleted: Although...t is well known ... [4]

New version 3/11/2016 8:31 PM

Formatted ... [5]



the Dnase I hypersensitive (DHS) sites from the ENCODE project (Thurman, et al., 2012). These annotation sets represent 3 different orders of magnitude in size: the DRM set spans ~14,000 annotations, the TSS set spans ~30,000 annotations, and the DHS set spans ~3 million annotations. We tested MOAT-a's running time on these 3 annotation sets with the number of random bins  $n = 1000$ , the results of which are shown in Table 1. It is clear that when scaling up to very large datasets, the CPU version's runtime increases considerably, while the GPU version runtime rises very gradually. MOAT-a's running time is not affected by the number of variants (data not shown).

Due to the relative lack of verified noncoding regulatory elements associated with cancer, it is difficult to assess the accuracy of MOAT's predictions. Nevertheless, we demonstrate MOAT's usefulness for finding elevated mutation burdens in genomic elements by identifying highly mutated GENCOD transcription start sites, promoters, and distal regulatory modules, using the aforementioned pancancer variant dataset. TERT, which has well-documented cancer-associated promoter mutations (Vinagre, et al., 2013), was found to have two TSSes with significant mutation burden (both had BH-corrected p-values of zero). Other well-known cancer-associated TSS sites, including TP53, LMO3, and AGAP5, also had significant mutation burdens (all had BH-corrected p-values of zero). After applying Benjamini-Hochberg (BH) false discovery rate correction (Benjamini and Hochberg, 1995) to all p-values, there were 5037 promoters, 1148 TSSes, and 305 DRMs with significant mutation burdens. These may be used as a shortlist for investigating and validating individual variants' associations with cancer.

#### 4.2 MOAT-v

Using the same set of cancer variants used in the MOAT-a tests, parallel MOAT-v's running time was evaluated across multiple CPU configurations to demonstrate the performance gains of the OpenMPI implementation. MOAT-v in OpenMPI is set up to run one master process on one of the available CPU cores, and use the rest for worker processes. Hence, the program must be run with 3 cores to get two cores to process the work simultaneously, 4 cores to get three cores to process the work simultaneously, etc. Table 2 represents the running time improvement relative to the number of workers added. This improvement scales close to linear with the number of workers, indicating that the load balancing between each CPU core is very evenly divided, enabling significant time savings when MOAT-v is run in parallel.

**Table 2.** Speed benchmark of MOAT-v with respect to the number of CPU cores assigned worker processes. Each time trial involved using MOAT-v to generate one permuted variant dataset using ~8 million input variants, and 1,000,000-bp bins.

# of worker CPU cores	Running time	Fold speedup
1	3hr44min	1.00x
2	1hr54min	1.97x
4	1hr4min	3.50x
8	40min	5.60x

MOAT-v was used on the same variant and annotation sets used to demonstrate MOAT-a's usefulness for finding elevated cancer mutation burdens. MOAT-v produced comparable results—the same known cancer-associated TSSes flagged as significant in MOAT-a were also flagged in MOAT-v. After applying BH correction to all p-values, there were 1394 promoters, 451 TSSes, and 109 DRMs with significant mutation burdens. Hence, MOAT-v appears to be the more conservative algorithm.

#### 5 DISCUSSION

Finding the genetic basis of disease enables the development of highly targeted therapies that promise to be far more effective than previous therapies. The current wave of next generation sequencing of thousands of genomes has provided the data necessary to find the precise phenomena responsible for the functional disruption that gives rise to disease phenotypes. Identification of genomic elements with a high mutation burden is useful for narrowing down the exact site of functional disruption. We introduce Mutations Overburdening Annotations Tool (MOAT), a new software tool to facilitate such analyses. We demonstrate the usefulness of this tool for flagging putative noncoding cancer drivers, and provide CUDA- and OpenMPI-accelerated versions that dramatically increase the speed of mutation burden analysis. Given the demand for efficient, meaningful analysis of genome sequence data that is now being produced at very high rate, we consider MOAT's provision of such analysis for genetic disease drivers quite timely.

**Funding:** This work was supported by the National Institutes of Health [5U41HG007000-04].

#### REFERENCES

Alexandrov, L.B., et al. Signatures of mutational processes in human cancer. *Nature* 2013;500(7463):415-421.

Benjamini, Y. and Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society. Series B (Methodological)*. 1995;57(1):289-300.

Gabriel, E., et al. Open MPI: Goals, concept, and design of a next generation MPI implementation. *Springer* 2004:97-104.

Harrow, J., et al. GENCODE: the reference human genome annotation for The ENCODE Project. *Genome research* 2012;22(9):1760-1774.

Nickolls, J., et al. Scalable parallel programming with CUDA. *Queue* 2008;6(2):40-53.

Thurman, R.E., et al. The accessible chromatin landscape of the human genome. *Nature* 2012;489(7414):75-82.

Vinagre, J., et al. Frequency of TERT promoter mutations in human cancers. *Nature communications* 2013;4:2185.

Wang, K., et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. *Nature genetics* 2014;46(6):573-582.

Yip, K.Y., et al. Classification of human genomic regions based on experimentally determined binding sites of more than 100 transcription-related factors. *Genome biology* 2012;13(9):R48.

New version 3/11/2016 8:31 PM  
Deleted: 200...30,000 annotations, &... [32]

New version 3/11/2016 8:31 PM  
Formatted: ParaNoInd

New version 3/11/2016 8:31 PM  
Deleted: : 0.01...of zero). Other wel... [33]

New version 3/11/2016 8:31 PM  
Deleted: a GPGPU...UDA- and Op... [34]

New version 3/11/2016 8:31 PM  
Deleted: ACKNOWLEDGEMENT... [35]

New version 3/11/2016 8:31 PM  
Formatted: ParaNoInd

New version 3/11/2016 8:31 PM  
Deleted: 7

New version 3/11/2016 8:31 PM  
Deleted: Number

New version 3/11/2016 8:31 PM  
Deleted: 14hr54min

New version 3/11/2016 8:31 PM  
Deleted: .

New version 3/11/2016 8:31 PM  
Deleted: 7hr56min

New version 3/11/2016 8:31 PM  
Deleted: 88x

New version 3/11/2016 8:31 PM  
Deleted: 4hr31min

New version 3/11/2016 8:31 PM  
Deleted: 30x

New version 3/11/2016 8:31 PM  
Deleted: 2hr39min

New version 3/11/2016 8:31 PM  
Deleted: 62x

New version 3/11/2016 8:31 PM  
Deleted: .